Project Grant R33CA291197
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$374K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30332, USA
Similar Awards
This federal Project Grant award for $716,314.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop novel therapeutics targeting FGFR2 alterations in gastroesophageal adenocarcinoma (GEA). The key products and services to be delivered include: Utilizing novel immune-competent mouse models of FGFR2-altered GEA to develop and test highly efficacious FGFR2 biparatopic antibodies (BIPABs) and FGFR2-targeted antibody-drug conjugates (ADCs), alone or in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,506,651.00 to Virginia Commonwealth University to evaluate a new agent, PEPDG278D, for overcoming drug resistance in non-small cell lung cancer (NSCLC). The key objectives are to: Assess PEPDG278D for inhibiting oncogenic signaling and anti-tumor activity in NSCLC cells and tumors expressing wild-type EGFR, and compare it to the approved EGFR-directed monoclonal antibody necitumumab....
The federal Project Grant award of $876,686.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by Cedars-Sinai Medical Center to unravel genomic rearrangements in epidermal growth factor (EGF)-mutant non-small cell lung cancer (NSCLC) and investigate mechanisms underlying resistance to tyrosine kinase inhibitors. This 3-year research project, commencing on May 15, 2025 and concluding on May 14, 2028, aims to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $244,228 to the University of Texas MD Anderson Cancer Center to develop a comprehensive proteomics-based approach to accurately map patient tumor samples to preclinical lung cancer models. The key products and services to be delivered include: (1) expanding proteomics profiling of lung cancer patient-derived xenograft (PDX) models using the reverse-phase protein...
This federal Project Grant award, issued by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate the molecular mechanisms underlying the adeno-to-squamous transition in non-small cell lung cancer treatment. The $703,410 award, with a project period from January 16, 2025 to December 31, 2029, aims to identify vulnerabilities in the chromatin regulators driving this adaptive...
This $627,833 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) aims to develop an informatics platform that integrates molecular and pathological data from various lung cancer preclinical models and patient tumors. The goal is to assess the fidelity of these preclinical models through comparative analyses. The University of Texas Southwestern Medical Center, the prime awardee, will work with Duke University as a sub-awardee to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $696,569 to New York University School of Medicine to conduct research aimed at developing novel therapies for lung cancer. The key objectives are to: 1) characterize the impact of the protein lipocalin 2 (LCN2) on the tumor microenvironment, 2) develop antibody-based therapeutics that interfere with LCN2 and assess their efficacy as monotherapy and in combination with immune checkpoint...
This federal Project Grant award of $449,196 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research at The University of Texas Southwestern Medical Center to investigate mechanisms of resistance to tyrosine kinase inhibitor (TKI) therapy in cancer. The research aims to determine how TKI treatment induces rapid sumoylation (a type of post-translational modification) of receptor tyrosine kinases (RTKs), which changes their function from kinases to adaptor...
This $216,460 federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at Case Western Reserve University to define the features of the neoantigen-specific T cell response against the common EGFR L858R mutation in lung cancer. The objective is to understand how the L858R mutation generates an immunogenic neoantigen that can provoke T cell-mediated anti-tumor immunity. Key activities include: Fully characterizing the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,418,424 to Tigatx Inc., a small business located in Boston, MA, to support the late-stage development and de-risking of a novel monoclonal antibody immunotherapy called TIGA-001 for EGFR-positive solid cancers, with a focus on non-small cell lung cancer (NSCLC). The award will fund activities to progress TIGA-001 into clinical testing, including chemistry, manufacturing, and controls...